Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Investment analysts at Oppenheimer issued their FY2021 EPS estimates for Tarsus Pharmaceuticals in a report issued on Monday, November 22nd. Oppenheimer analyst F. Brisebois anticipates that the company will earn ($0.48) per share for the year. Oppenheimer currently has a “Outperform” rating and a $55.00 target price on the stock. Oppenheimer also issued estimates for Tarsus Pharmaceuticals’ Q4 2021 earnings at ($0.54) EPS, Q1 2022 earnings at ($0.63) EPS, Q2 2022 earnings at ($1.09) EPS, Q3 2022 earnings at ($1.09) EPS, Q4 2022 earnings at ($1.17) EPS and FY2022 earnings at ($3.99) EPS.
Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Tuesday, November 9th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.34).
Shares of TARS opened at $27.70 on Thursday. The business has a 50-day moving average of $24.92. Tarsus Pharmaceuticals has a 1-year low of $19.67 and a 1-year high of $63.69.
Several institutional investors and hedge funds have recently modified their holdings of the company. TimesSquare Capital Management LLC lifted its stake in shares of Tarsus Pharmaceuticals by 52.0% during the second quarter. TimesSquare Capital Management LLC now owns 686,705 shares of the company’s stock valued at $19,901,000 after acquiring an additional 234,805 shares during the period. Jefferies Group LLC bought a new stake in shares of Tarsus Pharmaceuticals in the second quarter worth about $12,838,000. BlackRock Inc. increased its holdings in shares of Tarsus Pharmaceuticals by 0.7% in the third quarter. BlackRock Inc. now owns 441,620 shares of the company’s stock worth $9,519,000 after acquiring an additional 3,264 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Tarsus Pharmaceuticals by 56.1% in the second quarter. Vanguard Group Inc. now owns 426,045 shares of the company’s stock worth $12,347,000 after acquiring an additional 153,055 shares in the last quarter. Finally, Sands Capital Ventures LLC bought a new position in shares of Tarsus Pharmaceuticals during the third quarter worth about $5,603,000. 63.50% of the stock is currently owned by institutional investors and hedge funds.
In related news, CEO Bobak R. Azamian sold 5,531 shares of the business’s stock in a transaction on Tuesday, October 12th. The stock was sold at an average price of $26.30, for a total value of $145,465.30. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Aziz Mottiwala sold 1,889 shares of the business’s stock in a transaction on Monday, November 8th. The stock was sold at an average price of $28.11, for a total value of $53,099.79. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 33,914 shares of company stock valued at $889,523. Corporate insiders own 33.08% of the company’s stock.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Further Reading: What are popular green investing opportunities?
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.